Case 1:12-cv-00367-GMS Document 35 Filed 02/01/13 Page 1 of 40 PagelD #: 279
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`) )
`
`) )
`
`CUBIST PHARMACEUTICALS, INC.,
`
`Plaintiff,
`
`) CA. No. 12-367 (GMS)
`)
`(CONSOLIDATED)
`
`) )
`
`)
`
`Defendant.
`
`v.
`
`HOSPIRA, INC,
`
`JOINT CLAIM CONSTRUCTION CHARTS FOR THE PATENTS BEING
`
`ASSERTED BY CUBIST PHARMACEUTICALS, INC.
`
`The parties have met and conferred, and present the following Joint Claim Construction
`
`Charts for the patents being asserted by Cubist Pharmaceuticals, Inc.
`
`I. Stigulated Constructions. During the meet and confer process, the parties
`
`agreed to the claim construction for twelve claim terms from US. Patent Nos. 6,468,967,
`
`6,852,689, RE39,071, 8,129,342, and 8,058,238 as set foith in Exhibit A. The parties jointly and
`
`respectfully submit that, if the Court deems it appropriate, the Court include these agreed-upon
`
`claim constructions in the ultimate claim construction order. In the alternative, the parties agree
`
`that these agreed-upon constructions are binding between the parties.
`
`11. Claim Terms Reguiring Construction By The Court. The parties’ Joint
`
`Claim Construction Charts for US. Patent Nos. 6,468,967, 6,852,689, RE39,071, 8,129,342, and
`
`8,058,238 are attached as Exhibits B through D. Exhibit B summarizes the disputed claim terms
`
`and the parties’ proposed constructions for the five patents. Exhibit C lists the disputed claim term
`
`from US. Patent Nos. 6,468,967, 6,852,689, 8,129,342, and 8,058,238, and Exhibit D lists the
`
`disputed claim term from US. Patent No. RE39,071, as well as the parties’ proposed constructions
`
`and the evidence the parties rely upon in support of their proposed constructions for the patents.
`
`Page 1
`
`1
`
`CUBIST 2207
`AGILA v. CUBIST
`
`IPR2015—00143
`
`CUBIST 2207
`AGILA v. CUBIST
`IPR2015-00143
`
`Page 1
`
`

`

`Case 1:12-cv-00367-GMS Document 35 Filed 02/01/13 Page 2 of 40 PagelD #: 280
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`PHILLIPS, GOLDMAN & SPENCE, PA
`
`[51 Mafleffen Woreiéa
`Jack B. Blumenfeld (#1014)
`Maryellen Noreika (#3208)
`1201 North Market Street
`PO Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@mnat.com
`mnoreika@mnat.com
`
`[51 Zofin ( ._ ffiiffigs, 21’.
`John C. Phllhps, Jr. (No. 110)
`Megan C- Haney (NO- 5016)
`1200 North Broom Street
`Wilmington, DE 19806
`Tel- (302) 655-4200
`Fax (302) 655-4210
`Jcp@pgslaw.com
`mch@pgslaw.com
`
`OF COUNSEL:
`
`OF COUNSEL:
`
`William F, Lee
`.
`.
`
`1151581]'fion010
`“‘1 y
`e an
`WILMER CUTLER PICKERING HALE
`AND DORR LLP
`60 State Street
`
`Boston, MA 02109
`(617) 526-6000
`
`Attorneysfor Plaintifl Cubist Pharmaceuticals,
`Inc.
`
`James F. Hurst
`WINSTON & STRAWN LLP
`
`35 W. Wacker Drive
`Chicago, Illinois 60601
`(3 12) 558-5600
`E-mail: jhurst@winston.com
`
`Gail J. Standish
`Peter E. Perkowski
`WINSTON & STRAWN LLP
`
`333 S- Grand Avenue, Suite 3800
`Los Angeles, California 90071
`(213) 615-1700
`E-mail : gstandish@winston. com
`E-mail: pperkowski@winston.com
`
`Attorneys for Defendant and Counterclaim
`PlaintiflHOSPIRA, INC.
`
`February 1, 2013
`
`6982415
`
`Page 2
`
`Page 2
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 3 of 40 PagelD #: 281
`
`List of Agreed Upon Claim Term Constructions for U.S. Patent Nos. 6,468,967, 6,852,689, RE39,071, 8,129,342, and 8,058,238
`
`Exhibit A
`
`Claim Term
`Agreed-Upon Construction
`
`
`U.S. Patent Nos. 8,058,238 and 8,129,342
`
`
`“daptomycin that is substantially free of [another compound]”
`
`(Claims 3-5, 7-9, 50, 55, 56, 58, 61, 62, 64, 87, 88, 90, 165-175 of
`the ‘238 patent)
`
`“the other compound is present in an amount that is no more than
`1% of the amount of the daptomycin preparation”
`
`(Claims 10, 11, 16 of the ‘342 patent)
`
`
`
`
`”
`
`“daptomycin that is essentially free of [another compound]”
`
`(Claims 4—5, 9, 50, 56, 59, 62, 65, 88, 91, 165-175, 190 ofthe ‘238
`patent)
`
`(Claims 3, 32, 42 of the ‘342 patent)
`
`“anhydro-daptomycin”
`
`(Claims 3-5, 7, 50, 55, 56, 61, 62, 87, 88, 165-175, 190 ofthe ‘238
`patent)
`
`(Claims 1, 3-16, 18, 21-23, 32, 33, 41, 42, 53 ofthe ‘342 patent)
`
`Page 3
`
` “the other compound is present in an amount that is no more than
`
`0.5% of the amount of the daptomycin preparation”
`
`“The daptomycin derivative in which the (x-aspartyl group of
`daptomycin is transpeptidated to an anhydro-succinimido group,
`i. e.
`
`OJ:
`”Op/V J) 1
`/‘
`‘
`NH \
`17 O
`FM
`\
`I
`no
`[#00
`0
`NH
`o=(\
`NH
`0:
`2
`’
`>=o
`N
`HN
`o¥2~o
`\ W ‘ i n?”
`Yd Y b
`
`N
`H
`
`o
`)L Q
`‘0
`co,“
`
`00mg
`o
`H
`N‘
`
`H 0
`N—‘L‘(CH]ECHJ
`\
`/
`1
`/
`N
`H
`
`
`
`Page 3
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 4 of 40 PagelD #: 282
`
`Claim Term
`Agreed-Upon Construction
`
`“The daptomycin derivative that contains a [3-aspartyl group
`instead of an (x-aspartyl group, i. e.,
`o
`NH2
`\
`\ /
`‘V 0
`\
`M
`l
`1
`Ho\ (:00
`u
`7
`NH
`/
`NH
`0%
`>10
`NHOH
`H
`HN
`ofio
`i
`H
`O h\
`o
`/
`HNWXN/UVN \D
`
`cow?
`H7%
`H
`o
`coat-1
`NH2
`
`Hitcnmcm
`N,
`/
`
`”
`
`“B-isomer of daptomycin”
`
`(Claims 3-5, 7, 50, 55, 56, 61, 62, 87, 88, 165-175 ofthe ‘238
`patent)
`
`(Claims 1, 3-16, 21-23, 32, 33, 41, 42, 53 ofthe ‘342 patent)
`
`HOZC
`
`NH #0
`0
`o
`
` “conditions effective to form daptomycin [micelles/aggregates]”
` “conditions that result in the formation of daptomycin
`
`
`
`
`“micelle” / “daptomycin micelle”
`
`(Claims 21-35, 37-40, 42-45, 99, 104, 106, 107, 108, 131, 138,
`143, 145, 146, 147, 165-174, 176-180, 184, 185 ofthe ‘238 patent)
`
`“aggregates of amphipathic molecules” / “aggregates comprising
`daptomycin”
`
`(Claims 22-23, 30-49 of the ‘342 patent)
`
`“aggregate” / “daptomycin aggregate”
`
`(Claims 3-5, 7-9, 49-52, 55, 56, 58, 59, 61, 62, 64, 65, 85, 87, 88,
`90-109, 113-123, 125-148,151-161,164-175,179, 183-187, 189,
`190 of the ‘238 patent)
`
`(Claims 1, 3-23, 25-29, 50-54 of the ‘342 patent)
`
`“associated molecules including but not limited to micelles” /
`“associated molecules comprising daptomycin including but not
`limited to daptomycin micelles”
`
`(Claims 3-5, 7-9, 37-40, 42-43, 93-107, 125-146, 166-174,
`
`micelles/aggregates, including but not limited to one or more of the
`daptomycin concentration, temperature, salt concentration, and/or
`pH of a daptomycin solution”
`
`Page 4
`
`Page 4
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 5 of 40 PagelD #: 283
`
`Claim Term
`Agreed-Upon Construction
`
`176-179 of the ‘238 patent)
`
`(Claims 5-6 of the ‘342 patent)
`
`“daptomycin purified by a process comprising the steps of:”
`
`(Claims 3-5, 7, 166-174 of the ‘238 patent)
`
`(Claims 30-39, 50-54 of the ‘342 patent)
`
`“daptomycin that has been purified by a process including, but not
`limited to, the following steps”
`
` “a compound of formula 1, a compound of formula 2, and a
`
`
`
`“the other compound is present in an amount that is no more than
`“daptomycin that is free of [another c0mp0und]”
`0.1% of the amount of the daptomycin preparation”
`(Claims 50, 165-175 of the ‘238 patent)
`“at least 98% of a sample is daptomycin”
`“essentially pure daptomycin”
`
`(Claims 50, 165-175 of the ‘238 patent)
`“purified daptomycin”
`
`“daptomycin that is substantially pure, essentially pure, or
`substantially free, essentially free, or free of another compound”
`
`(Claims 8—9, 49-52, 55, 56, 58, 59, 61, 62, 64, 65, 85, 87,
`88, 90-109,113-123,125-148,151-161, 164-180,183-
`
`187, 189, 190 of the ‘238 patent)
`U.S. Patent No. RE 39 071
`
`compound of formula 3, present together and totaling 100% by
`weight of the combination”
`
`“a combination of a compound of formula 1, a compound of
`formula 2, and a compound of formula 3”
`
`(Claims 18, 19, 26, 28 of the ‘071 patent)
`
`Page 5
`
`Page 5
`
`

`

`The compound described in the Baltz
`The cyclic lipopeptide antibiotic derived from
`article at Fig. 1a (Biotechnology of
`the fermentation of Streptomyces roseosporus,
`comprised of a decanoyl side chain linked to the Antibiotics, 2‘ld Ed., ed. by Strohl,
`N—terminal tryptophan of a cyclic 13-amino acid 415-435 (1997)) and in the Tally article
`peptide, i.e.,
`at Fig. 1 (Exp. Opin. Invest. Drugs,
`8:1223-1238 (1999)), (i. e., having the
`L-Asn configuration)
`
`0|
`
`NH2
`
`H0 C/\/
`2
`HNJY
`HOLQCOO
`NH
`o=<
`
`NH,\
`0’0
`0
`0
`
`H020
`
`o
`
`NH
`</
`
`HN
`
`00%
`o
`
`“)1”
`
`0
`
`H
`
`H 0
`Nimfiws
`/N
`
`o
`
`N
`
`H
`
`0
`
`(LY146032) or a pharmaceutically acceptable
`salt thereof.
`
`/L—Asp\
`pm.
`(“K
`/
`us“
`I’M"
`\
`i
`m
`(lrfllteo)3-M;Glu
`LR
`2g.“
`
`01!
`
`by:
`We
`
`
`
`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 6 of 40 PagelD #: 284
`
`Summa of Pro osed Claim Constructions for U.S. Patent Nos. 6 468 967 6 852 689 8 129 342 8 058 238 and RE39 071
`
`
`
`Hospira’s Proposed Construction
`Cubist’s Proposed Construction
`Term To Be Construed
`
`
`Exhibit B
`
`U.S. Patent Nos. 6 468 967 6 852 689 8 129 42 and 8 058 238
`
`
`“daptomycin”
`
`(Claims 3-5, 16-17, 27-28, 34—35,
`42-45 of the ‘967 patent)
`
`(Claims 48-52 of the ‘689 patent)
`
`(Claims 3-5, 7-9, 21-35, 37-40, 42-45,
`49-52, 55, 56, 58, 59, 61, 62, 64, 65,
`85, 87, 88, 90—109, 113—123, 125-148,
`151-161, 164-180, 183-187, 189, 190
`of the ‘238 patent)
`'
`
`L
`
`(Claims 1, 3-23, 25-54 ofthe 342
`
`patent)
`
`Page 6
`
`
`
`Page 6
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 7 of 40 PagelD #: 285
`
`Hospira’s Proposed Construction
`Cubist’s Proposed Construction
`Term To Be Construed
`
`
`US. Patent No. RE393071
`
`“formula 3 compound”/ “compound of A11 A21978C cyclic peptide of
`The FORMULA 3 compound as
`formula 3”
`recited in claims 18 and 26 that
`
`re—issued on April 18, 2006 (i. e. ,
`having the L—Asn configuration)
`
`FORll-fl -'LA 3
`
`L-Asp
`/ \Gly
`D—Ala
`l
`D-Ser
`
`L-Asp
`
`L-Orn
`
`3M6
`
`l/rl/
`
`\G
`
`ly‘\\
`
`.
`(Clalms 18, 26, 28 0f the ‘071 patent)
`
`FORMULA 1.
`_
`
`
`
`R“
`
`wherein RN is n—decanoyl (i.e., LY 146032).
`
`Page 7
`
`Page 7
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 8 of 40 PagelD #: 286
`
`Joint Claim Chart for U.S. Patent Nos. 6,468,967, 6,852,689, 8,129,342, and 8,058,238
`
`Exhibit C
`
`Proposed Construction of Disputed Claim Term with Citations to Supporting Evidence
`
`
`Intrinsic Evidence
`Hospira’s Proposed
`Intrinsic Evidence
`Cubist’s Proposed
`Term To Be
`Construed
`Construction
`Supporting Cubist’s
`Construction
`Supporting Hospira’s
`Construction
`Construction
`
`
`‘967 Patent Specification The compound described
`in the Baltz article at Fig.
`1a (Biotechnology of
`Antibiotics, 2nd Ed.) ed. by Abstract
`Strohl, 415435 (1997))
`and in the Tally article at
`Fig. 1 (Exp. Opin. Invest.
`Drugs, 8:1223- 1238
`(1999)), (i. e., having the
`L-Asn configuration)
`
`‘967 Patent and File
`Histom
`
`C01. 1, 1n. 2 — C01. 3,
`In. 12
`
`C01. 14, lns. 38—48
`
`Baltz et al.,
`Biotechnology of
`Antibiotics, 2’1d Ed., ed.
`by Strohl, 415-435
`(1997) (cited at C01. 1,
`lns. 40-5 1 )
`
`/L-Asp\
`D-Ala
`my
`DS
`
`L-Mp
`
`er
`(blhrw)3-MeGlu
`
`Tally et al., Exp. Opin.
`Invest. Drugs,
`8:1223-1238 (1999)
`(cited at C01. 1, lns.
`20-38)
`
`
`
` C01. 1,1ns. 18-51
`
`C01. 1, 1115. 10-13
`
`C01. 1, In. 63 — C01. 2, In.
`43
`
`C01. 3, lns. 14—28
`
`C01. 3, lns. 36-41
`
`C01. 3, In. 45 — C01. 4, In.
`48
`
`C01. 4, In. 64 — C01. 5, l.
`13
`
`C01. 5, lns. 41-56
`
`C01. 5, l. 65 — C01. 6, 1n. 1
`
`“Daptomycin”
`
`(Claims 3-5,
`16-17, 27-28,
`34-35, 42-45 of
`the ‘967 patent)
`
`(Claims 48-52 of
`the ‘689 patent)
`
`(Claims 3-5, 7-9,
`21-35, 37-40,
`42-45, 49-52, 55,
`56, 58, 59, 61, 62,
`64, 65, 85, 87, 88,
`90-109, 113-123,
`125-148,
`151-161,164—180,
`183-187, 189, 190
`of the ‘238 patent)
`
`“The cyclic lipopeptide
`antibiotic derived from the
`fermentation of Streptomyces
`roseosporus, comprised of a
`decanoyl side chain linked to
`the N—terminal tryptophan of a
`cyclic 13-amino acid peptide,
`i.e.
`
`NH
`i
`l
`HWY )0
`HO
`)=oo
`0
`NH
`0
`Mi
`0:8
`
`0,
`
`\/
`d
`
`NH
`HN
`90
`
`2
`
`CONH
`O
`“\gN
`0
`i
`H
`OO,H
`
`0
`NJ—rcmm,
`N
`/
`“
`
`(LY146032) or a
`pharmaceutically acceptable
`salt thereof.”
`
`Page 8
`
`(Claims 1, 3-23,
`C01. 6, lns. 9-12
`25-54 of the ‘342
`9/11/00 Declaration of
`
`Page 8
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 9 of 40 PagelD #: 287
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`Intrinsic Evidence
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`patent)
`
`Col. 6, lns. 17-38
`
`2 C
`
`ol. 8, lns. 8-12
`
`Col. 8, lns. 15-17
`
`Col. 8, lns. 21-46
`
`Col. 9, In. 25 — Col. 12,
`In. 30 (Examples 1, 2)
`
`Col. 12, In. 62 — Col. 14,
`In. 27 (Examples 4, 5)
`
`Col. 14, In. 50 — Col. 15,
`In. 2 (Claims 1-7)
`
`Col. 15, In. 27 — Col. 16,
`In. 29 (Claims 12-28)
`
`Col. 16, lns. 33-62
`(Claims 32-45)
`
`Figures 1-3
`‘
`
`2
`
`Page 9
`
` Col. 7, In. 17 — Col. 8, 1n.
`
`Francis Tally at fl5-6
`
`‘238 Patent and File
`
`Histog
`
`Abstract
`
`Col. 1, In. 21 — Col. 3,
`In. 46
`
`C01. 7, lns. 2-27
`
`Col. 37, lns. 30—40
`
`Claims 49, 50, 66, and
`191
`
`Baltz et al.,
`Biotechnology of
`Antibiotics, 2’1d Ed., ed.
`by Sirohl, 415-435
`(1997) (cited at Col. 1,
`lns. 58-66)
`
`
`
`Tally et al., Exp. Opin.
`Invest. Drugs,
`8:1223-1238 (1999)
`(cited at Col. 1, lns.
`39_57)
`967 Patent Abstract
`
`US. Patent No. RE
`
`Page 9
`
`

`

`32,333 to Hamill (cited
`at Col. 2, lns. 13-19)
`
`US. Patent No. RE
`
`32,455 to Hamill (cited
`at Col. 2, lns. 13-19)
`
`US. Patent No. RE
`
`32,310 to Debono
`(cited at Col. 2, lns.
`20-27)
`
`US. Patent No. RE
`
`32,311 to Debono
`(cited at Col. 2, lns.
`20-27)
`
`US. Patent No.
`
`4,537,717 to Abbott
`(cited at Col. 2, lns.
`20-27)
`
`US. Patent No.
`
`4,482,487 to Abbott
`(cited at Col. 2, lns.
`20-27)
`
`US. Patent No.
`
`
`
`Col. 2, In. 51 — Col.11,
`In. 62
`4,524,135 to Abbott
`
`(cited at Col. 2, lns.
`
`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 10 of 40 PageID #: 288
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`Intrinsic Evidence
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`‘967 Patent File Histog
`
`9/ 1 1/2000 Amendment
`
`Action at pp. 6-21
`(CUBH 000794-809)
`
`9/11/2000 Declaration of
`
`Francis P. Tally Under 37
`C.F.R. § 1.132 at pp. 3-8
`(CUBH 000812-17)
`
`06/02/2000 Information
`
`Disclosure Statement at p.
`2 (CUBH 000845)
`
`01/07/2002 Amendment
`
`Under 37 C.F.R § 1.312
`at p. 2 (CUBH 000934)
`
`References Cited in the
`
`Specification or File
`Histog of the ‘967 Patent
`
`US. Patent No.
`RE32 310
`
` and Response to Oflice
`
`Page 10
`
`Page 10
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 11 of 40 PageID #: 289
`
`Term To Be
`
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
` US. Patent No.
` In. 62
`
`
`
`Col. 15, ln.45 — Col. 23,
`
`20-27)
`
`5,912,226 to Baker
`(cited at Col. 2, In. 65 —
`Col. 3, In. 46)
`
`Miao et al.,
`Daptomycin
`Biosynthesis in
`Streptomyces
`roseosporus: Cloning
`and Analysis of the
`Gene Cluster and
`
`Revision of Peptide
`Stereochemistry,
`Microbiology, 151:
`1507-23 (2005)
`
`US. Patent No.
`RE32 311
`
`Abstract
`
`Col. 1, ln. 9 — Col. 12, In.
`17
`
`C01. 17, In. 65 — Col. 43,
`In. 17
`
`US. Patent No.
`4 537 717
`
`Abstract
`
`Col. 1, In. 13 — Col. 7, In.
`68
`
`C01. 15,1n. 10 — Col. 32,
`In. 68
`
`US. Patent No.
`4 482 487
`
`Abstract
`
`Col. 1, In. 11 — Col. 6, 1n.
`
`Page 1 1
`
`Page 11
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 12 of 40 PageID #: 290
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`In. 58
` 61
`
`C01. 8,1n. 53 — C01. 13,
`In. 42
`
`C01. 22, In. 32 — C01. 33,
`In. 15
`
`US. Patent No.
`4 524 135
`
`Abstract
`
`C01. 1, In. 13 — C01. 6, In.
`56
`
`C01. 8, In. 47 — C01. 13,
`In. 40
`
`C01. 21, In. 60 — C01. 32,
`In. 30
`
`US. Patent No.
`RE32 333
`
`C01. 1, In. 40 — C01. 2, In.
`16
`
`C01 19, In. 62 — C01. 25,
`
`Page 12
`
`Page 12
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 13 of 40 PageID #: 291
`
`
`Intrinsic Evidence
`Intrinsic Evidence
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Construction
`
`Supporting Cubist’s
`Construction
`
`RE32 455
`
`C01. 1, In. 51 — C01. 2, In.
`25
`
`C01. 20, In. 4 — C01. 25,
`In. 65
`
`US. Patent No.
`4 800 157
`
`C01. 1, 111s. 1-64
`
`C01. 8, In. 40 — C01. 10,
`In. 29
`
`US. Patent No.
`4 874 843
`
`C01. 1,1n. 1 — C01. 5,1n.
`16
`
`
`
` US. Patent No.
`
`US. Patent No.
`4 885 243
`
`C01. 1, 1n. 1 — C01. 8, 1n. 7
`
`US. Patent N. 4 208 403
`
`
`Page 13
`
`Page 13
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 14 of 40 PageID #: 292
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`HOSP_CUB0005049-55)
` Abstract
`
`Col. 1, 1n. 1 — Col. 25, In.
`19
`
`Baltz, Lipopeptide
`Antibiotics Produced by
`Streptomyces
`roseosporus and
`Streptomycesfradiae,
`BIOTECHNOLOGY OF
`
`ANTIBIOTICS, 2d ed.
`415-435 (1997) at pp.
`415-16, 419-20, 423-26,
`430
`
`(HOSP_CUB0004829-30
`HOSP_CUB0004833-34,
`HOSP_CUB0004837—40,
`HOSP_CUB0004844)
`
`Tally et al., Daptomycin:
`A Novel Agentfor
`Gram-Positive Infections,
`EXP. OPIN. INVEST.
`DRUGS 8: 1223-1238
`
`(1999) at 1223, -24,
`1229-35
`
`(HOSP_CUB0005043-44
`
`Page 14
`
`Page 14
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 15 of 40 PageID #: 293
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Supporting Cubist’s
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Supporting Hospira’s
`Construction
`
`Dosing in Dogs
`Optimizes Daptomycin
`Safety, ANTIMICROBIAL
`AGENTS AND
`
`CHEMOTHERAPY, 44:
`2948-2953 (2000) at pp.
`2948, 2951-53 (CUB
`00487949, CUB
`00487952-54)
`
`Lee et al., Daptomycin
`versus Conventional
`
`Therapy in the Treatment
`ofEndocarditis and
`Bacteremia, ABSTRACTS
`OF THE INTERSCIENCE
`CONFERENCE ON
`ANTIMICROBIAL AGENTS
`
`
`
` Oleson et al., Once-Daily
`
`AND CHEMOTHERAPY,
`A88 5 , 1 991
`
`Sexton et al., The Use of
`Daptomycin, a
`Lipopeptide Antibiotic, in
`the Treatment of Gram
`Positive Infections in
`Man, ABSTRACTS OF THE
`INTERSCIENCE
`CONFERENCE ON
`
`Page 15
`
`Page 15
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 16 of 40 PageID #: 294
`
`
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`Intrinsic Evidence
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`ANTIMICROBIAL AGENTS
`
`01. 6, 111s. 11-14
`
`
`
`
`AND CHEMOTHERAPY,
`A932, 1988
`c
`
`689 Patent Specification
`
`C01. 1, 111s. 13-16
`
`C01. 1, 111s. 21-53
`
`Col.1, In. 65 — C01. 2, In.
`45
`
`C01. 3, 111s. 17-30
`
`C01. 3, 111s. 38-43
`
`C01. 3, In. 48 — C01. 4, In.
`50
`
`C01. 4, In. 66 — C01. 5, In.
`16
`
`C01. 5, 111s. 43-58
`
`C01. 5, In. 67 — C01. 6, 1n.
`
`3 C
`
`
`
`Page 16
`
`Page 16
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 17 of 40 PageID #: 295
`
`Intrinsic Evidence
`Hospira’s Proposed
`Intrinsic Evidence
`Cubist’s Proposed
`Term To Be
`Supporting Hospira’s
`Construction
`Supporting Cubist’s
`Construction
`Construed
`Construction
`Construction
`
`
`Col. 6, lns. 19-40
`
`Col. 7, In. 38 — Col. 8, 1n.
`
`4 C
`
`ol. 8, lns. 10-14
`
`
`
`
`
`Col. 8, lns. 17-19
`
`Col. 8, lns. 23-48
`
`Col. 9, In. 29 — Col. 12,
`In. 30 (Examples 1, 2)
`
`Col. 12, In. 63 — Col. 14,
`In. 25 (Examples 4, 5)
`
`Col. 14, lns. 48-62
`(Claims 1-5)
`
`Col. 15,1n. 21 — Col. 16,
`In. 65 (Claims 10-57)
`
`Figures 1-3
`
`‘689 Patent Abstract
`
`‘689 Patent File History
`
`02/20/2002 Information
`
`Disclosure Statement at p.
`
`10
`
`Page 17
`
`Page 17
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 18 of 40 PageID #: 296
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`Intrinsic Evidence
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
` References Cited in the
`
`2 (CUBH 001680)
`
`11/20/2002 Amendment
`
`at pp. 6-17 (CUBH
`001 53 0—41)
`
`Specification or File
`Histog of the ‘689 Patent
`
`US. Patent No.
`RE32 310
`
`C01. 2,1n. 51 — C01.11,
`In. 62
`
`C01. 15, ln.45 — C01. 23,
`In. 62
`
`US. Patent No.
`RE32 311
`
`Abstract
`
`C01. 1, 1n. 9 — C01. 12, In.
`17
`
`C01. 17, In. 65 — C01. 43,
`In. 17
`
`
`
`US. Patent No.
`
`11
`
`Page 18
`
`Page 18
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 19 of 40 PageID #: 297
`
`
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`Intrinsic Evidence
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`4 537 717
`
`
`
`Abstract
`
`C01. 1, In. 13 — C01. 7, In.
`68
`
`C01. 15,1n. 10 — C01. 32,
`In. 68
`
`US. Patent No.
`4 482 487
`
`Abstract
`
`C01. 1, In. 11 — C01. 6, In.
`61
`
`C01. 8,1n. 53 — C01. 13,
`In. 42
`
`C01. 22, In. 32 — C01. 33,
`In. 15
`
`US. Patent No.
`4 524 135
`
`Abstract
`
`
`
`
`C01. 1, In. 13 — C01. 6, 1n.
`
`12
`
`Page 19
`
`Page 19
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 20 of 40 PageID #: 298
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` 56
`
`C01. 8, In. 47 — C01. 13,
`In. 40
`
`C01. 21, In. 60 — C01. 32,
`In. 30
`
`US. Patent No.
`RE32 333
`
`C01. 1, In. 40 — C01. 2,
`In. 16
`
`C01 19, In. 62 — C01. 25,
`In. 58
`
`US. Patent No.
`RE32 455
`
`C01. 1, In. 51 — C01. 2, In.
`25
`
`C01. 20, In. 4 — C01. 25,
`In. 65
`
`US. Patent No.
`4 800 157
`
`C01. 1, 111s. 1-64
`
`13
`
`Page 20
`
`Page 20
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 21 of 40 PageID #: 299
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` C01. 8, In. 40 — C01. 10,
`
`In. 29
`
`US. Patent No.
`4 874 843
`
`C01. 1,1n. 1 — C01. 5,1n.
`16
`
`US. Patent No.
`4 885 243
`
`C01. 1, 1n. 1 — C01. 8, 1n. 7
`
`US. Patent N. 4 208 403
`
`Abstract
`
`C01. 1, 1n. 1 — C01. 25, In.
`19
`
`Baltz, Lipopeptide
`Antibiotics Produced by
`Streptomyces
`roseosporus and
`Streptomycesfradiae,
`BIOTECHNOLOGY OF
`
`ANTIBIOTICS, 2d ed.
`415-435 (1997) at pp.
`415-16, 419-20, 423-26,
`
`14
`
`Page 21
`
`Page 21
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 22 of 40 PageID #: 300
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` 430
`
`(HOSP_CUB0004829-30
`
`HOSP_CUB0004833-34,
`HOSP_CUB0004837—40,
`HOSP_CUB0004844)
`
`Tally et al., Daptomycin:
`A Novel Agentfor
`Gram-Positive Infections,
`EXP. OPIN. INVEST.
`DRUGS 8: 1223-1238
`
`(1999) at 1223, -24,
`1229-35
`
`(HOSP_CUB0005043-44
`HOSP_CUB0005049-55)
`
`Oleson et al., Once-Daily
`Dosing in Dogs
`Optimizes Daptomycin
`Safety, ANTIMICROBIAL
`AGENTS AND
`
`CHEMOTHERAPY, 44:
`2948-2953 (2000) at pp.
`2948, 2951-53 (CUB
`00487949, CUB
`00487952-54)
`
`Lee et al., Daptomycin
`versus Conventional
`
`15
`
`Page 22
`
`Page 22
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 23 of 40 PageID #: 301
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Cubist’s
`Construction
`
`Supporting Hospira’s
`Construction
`
` Therapy in the Treatment
`
`
`
`ofEndocarditis and
`Bacteremia, ABSTRACTS
`OF THE INTERSCIENCE
`CONFERENCE ON
`ANTIMICROBIAL AGENTS
`
`AND CHEMOTHERAPY,
`A88 5 , 1 991
`
`Sexton et al., The Use of
`Daptomycin, a
`Lipopeptide Antibiotic, in
`the Treatment of Gram
`Positive Infections in
`Man, ABSTRACTS OF THE
`INTERSCIENCE
`CONFERENCE ON
`ANTIMICROBIAL AGENTS
`
`AND CHEMOTHERAPY,
`A932, 1988
`
`‘238 Patent Specification:
`
`Fig. 1.
`
`Col. 1, 111s. 21-25
`
`Col. 1, 111s. 39-57
`
`
`Col. 1, In. 57 — Col. 2, 1n.
`
`16
`
`Page 23
`
`Page 23
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 24 of 40 PageID #: 302
`
`
`Intrinsic Evidence
`Intrinsic Evidence
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Supporting Cubist’s
`Construction
`
`Supporting Hospira’s
`Construction
`
` 60
`
`
`
`C01. 3, 111s. 33-38
`
`C01. 4, In. 21
`
`C01. 5, 111s. 22-36
`
`C01. 7, 111s. 24-27
`
`C01. 9, lns 9-15
`
`C01. 9, 111s. 16-22
`
`C01. 14,1ns 13-30
`
`C01. 21, 111s. 8-17
`
`C01. 26, 111s. 46-49
`
`C01. 26, 111s. 56-60
`
`C01. 28, 111s. 1-18
`
`Cols. 30—37
`
`‘238 File History
`
`08/11/2009 Oflice Action
`at CUBH 001937
`
`
`17
`
`Page 24
`
`Page 24
`
`

`

`3/16/2010 Information
`Disclosure Statement at
`CUBH 001893
`
`Specification or File
`Histog of the ‘238 Patent
`
`US. Patent No.
`RE32 310
`
`C01. 2,1n. 51 — C01.11,
`In. 62
`
`C01. 15, In. 45 — C01. 23,
`In. 62
`
`US. Patent No.
`RE32 311
`
`Abstract
`
`C01. 1, 1n. 9 — C01. 12, In.
`17
`
`C01. 17, In. 65 — C01. 43,
`In. 17
`
` References Cited in the
`
`
`
`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 25 of 40 PageID #: 303
`
`Intrinsic Evidence
`Hospira’s Proposed
`Intrinsic Evidence
`Cubist’s Proposed
`Term To Be
`Construed
`Construction
`Supporting Cubist’s
`Construction
`Supporting Hospira’s
`Construction
`Construction
`
`
`US. Patent No.
`4 537 717
`
`
`18
`
`Page 25
`
`Page 25
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 26 of 40 PageID #: 304
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`Intrinsic Evidence
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`Abstract
`
`
`
`56
`
`C01. 1, In. 13 — C01. 7, In.
`68
`
`C01. 15,1n. 10 — C01. 32,
`In. 68
`
`US. Patent No.
`4 482 487
`
`Abstract
`
`C01. 1, In. 11 — C01. 6, In.
`61
`
`C01. 8,1n. 53 — C01. 13,
`In. 42
`
`C01. 22, In. 32 — C01. 33,
`In. 15
`
`US. Patent No.
`4 524 135
`
`Abstract
`
`C01. 1, In. 13 — C01. 6, In.
`
`C01. 8, In. 47 — C01. 13,
`
`19
`
`Page 26
`
`Page 26
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 27 of 40 PageID #: 305
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` In. 40
`
`C01. 21, In. 60 — C01. 32,
`In. 30
`
`US. Patent No.
`RE32 333
`
`C01. 1, In. 40 — C01. 2,
`ln.16
`
`C01 19, In. 62 — C01. 25,
`In. 58
`
`US. Patent No.
`RE32 455
`
`C01. 1, In. 51 — C01. 2, In.
`25
`
`C01. 20, In. 4 — C01. 25,
`In. 65
`
`US. Patent No.
`4 800 157
`
`C01. 1, 111s. 1-64
`
`C01. 8, In. 40 — C01. 10,
`In. 29
`
`20
`
`Page 27
`
`Page 27
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 28 of 40 PageID #: 306
`
`
`Intrinsic Evidence
`Intrinsic Evidence
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Supporting Cubist’s
`Construction
`
`Supporting Hospira’s
`Construction
`
` US. Patent No.
`
`
`
`4 874 843
`
`Col. 1,1n. 1 — Col. 5,1n.
`16
`
`US. Patent No.
`4 885 243
`
`Col. 1, 1n. 1 — Col. 8, 1n. 7
`
`US. Patent N. 4 208 403
`
`Abstract
`
`Col. 1, 1n. 1 — Col. 25, In.
`19
`
`Baltz, Lipopeptide
`Antibiotics Produced by
`Streptomyces
`roseosporus and
`Streptomycesfradiae,
`BIOTECHNOLOGY OF
`
`ANTIBIOTICS, 2d ed.
`415-435 (1997) at pp.
`415-16, 419-20, 423-26,
`430
`
`(HOSP_CUB0004829-30
`
`HOSP CUB0004833-34,
`
`21
`
`Page 28
`
`Page 28
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 29 of 40 PageID #: 307
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` HOSP_CUB0004837—40,
`
`HOSP_CUB0004844)
`
`Tally et al., Daptomycin:
`A Novel Agentfor
`Gram-Positive Infections,
`Exp. Opin. Invest. Drugs
`8: 1223-1238 (1999) at pp.
`1223, -24, 1229-35
`(HOSP_CUB0005043-44
`HOSP_CUB0005049-55)
`
`Miao et al., Daptomycin
`Biosynthesis in
`Streptomyces
`roseosporus: Cloning and
`Analysis ofthe Gene
`Cluster and Revision of
`Peptide Stereochemistry,
`MICROBIOLOGY 1 51 I
`
`1507-23 (2005) at pp.
`1507-08, 1512, 1520-21
`(CUBH 000441 -42,
`CUBH 000446, CUBH
`000454-55)
`
`‘342 Patent Specification:
`
`Fig. 1.
`
`22
`
`Page 29
`
`Page 29
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 30 of 40 PageID #: 308
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` C01. 1, 111s. 18-22
`
`C01. 1, In. 36 — C01. 2,1n.
`57
`
`C01. 3, 111s. 30—36
`
`C01. 4, In. 18
`
`C01. 5, 111s. 17-31
`
`C01. 7, 111s. 17-20
`
`C01. 9, 111s. 4-1.
`
`C01. 9,1ns 11-17
`
`C01. 14, 111s. 8-12
`
`C01. 14, 111s. 17-26
`
`C01. 21, 111s. 1-11
`
`C01. 26, 111s. 39-42
`
`C01. 26, 111s. 49-53
`
`C01 27, In. 60 — C01. 28,
`In. 10
`
`23
`
`Page 30
`
`Page 30
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 31 of 40 PageID #: 309
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` Cols. 30-37
`
`‘342 File History
`
`07/29/2011 Office Action
`at CUBH 000283
`
`08/12/201 1 Information
`Disclosure Statement at
`CUBH 000199
`
`12/08/2011 Information
`Disclosure Statement at
`CUBH 000192
`
`References Cited in the
`
`Specification or File
`Histog of the ‘342 Patent
`
`Cubicin® (daptomycin
`for injection) Label 1004
`— September 2003
`
`Cubicin® (daptomycin
`for injection) Label
`1004-1 — Revised August
`200
`
`Cubicin® (daptomycin
`for injection) Label
`
`24
`
`Page 31
`
`Page 31
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13
`
`Page 32 of 40 PageID #: 310
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` 1004-2 — Revised June
`
`2005
`
`Cubicin® (daptomycin
`for injection) Label
`1004-10-1 August 2010
`
`US. Patent No.
`RE32 310
`
`C01. 2,1n. 51 — C01.11,
`In. 62
`
`C01. 15, ln.45 — C01. 23,
`In. 62
`
`US. Patent No.
`RE32 311
`
`Abstract
`
`C01. 1, 1n. 9 — C01. 12, In.
`17
`
`C01. 17, In. 65 — C01. 43,
`In. 17
`
`US. Patent No.
`4 537 717
`
`25
`
`Page 32
`
`Page 32
`
`

`

`Case 1:12—cv—OO367—GMS Document 35 Filed 02/01/13 Page 33 of 40 PageID #: 311
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`Intrinsic Evidence
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`Abstract
`
`
`
`56
`
`C01. 1, In. 13 — C01. 7, In.
`68
`
`C01. 15,1n. 10 — C01. 32,
`In. 68
`
`US. Patent No.
`4 482 487
`
`Abstract
`
`C01. 1, In. 11 — C01. 6, In.
`61
`
`C01. 8,1n. 53 — C01. 13,
`In. 42
`
`C01. 22, In. 32 — C01. 33,
`In. 15
`
`US. Patent No.
`4 524 135
`
`Abstract
`
`C01. 1, In. 13 — C01. 6, In.
`
`C01. 8, In. 47 — C01. 13,
`
`26
`
`Page 33
`
`Page 33
`
`

`

`Case 1:12—cv—OO367—GMS Document 35 Filed 02/01/13
`
`Page 34 of 40 PageID #: 312
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` In. 40
`
`C01. 21, In. 60 — C01. 32,
`In. 30
`
`US. Patent No.
`RE32 333
`
`C01. 1, In. 40 — C01. 2, In.
`16
`
`C01 19, In. 62 — C01. 25,
`In. 58
`
`US. Patent No.
`RE32 455
`
`C01. 1, In. 51 — C01. 2, In.
`25
`
`C01. 20, In. 4 — C01. 25,
`In. 65
`
`US. Patent No.
`4 800 157
`
`C01. 1, 111s. 1-64
`
`C01. 8, In. 40 — C01. 10,
`In. 29
`
`27
`
`Page 34
`
`Page 34
`
`

`

`Case 1:12—cv—OO367—GMS Document 35 Filed 02/01/13 Page 35 of 40 PageID #: 313
`
`
`Intrinsic Evidence
`Intrinsic Evidence
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Supporting Cubist’s
`Construction
`
`Supporting Hospira’s
`Construction
`
` US. Patent No.
`
`
`
`4 874 843
`
`Col. 1,1n. 1 — Col. 5,1n.
`16
`
`US. Patent No.
`4 885 243
`
`Col. 1, 1n. 1 — Col. 8, 1n. 7
`
`US. Patent N. 4 208 403
`
`Abstract
`
`Col. 1, 1n. 1 — Col. 25, In.
`19
`
`Baltz, Lipopeptide
`Antibiotics Produced by
`Streptomyces
`roseosporus and
`Streptomycesfradiae,
`BIOTECHNOLOGY OF
`
`ANTIBIOTICS, 2d ed.
`415-435 (1997) at pp.
`415-16, 419-20, 423-26,
`430
`
`(HOSP_CUB0004829-30
`
`HOSP CUB0004833-34,
`
`28
`
`Page 35
`
`Page 35
`
`

`

`Case 1:12—cv—OO367—GMS Document 35 Filed 02/01/13
`
`Page 36 of 40 PageID #: 314
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Intrinsic Evidence
`
`Intrinsic Evidence
`
`Hospira’s Proposed
`Construction
`
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
`
` HOSP_CUB0004837—40,
`
`HOSP_CUB0004844)
`
`Tally et al., Daptomycin:
`A Novel Agentfor
`Gram-Positive Infections,
`Exp. Opin. Invest. Drugs
`8: 1223-1238 (1999) at pp.
`1223, -24, 1229-35
`(HOSP_CUB0005043-44
`HOSP_CUB0005049-55)
`
`Miao et al., Daptomycin
`Biosynthesis in
`Streptomyces
`roseosporus: Cloning and
`Analysis ofthe Gene
`Cluster and Revision of
`Peptide Stereochemistry,
`MICROBIOLOGY 1 51 I
`
`1507-23 (2005) at pp.
`1507-08, 1512, 1520-21
`(CUBH 000441 -42,
`CUBH 000446, CUBH
`000454-55)
`
`29
`
`Page 36
`
`Page 36
`
`

`

`Case 1:12—cv—00367—GMS Document 35 Filed 02/01/13 Page 37 of 40 PageID #: 315
`
`Exhibit D
`
`Joint Claim Chart for U.S. Patent Nos. RE39,071
`
`Proposed Construction of Disputed Claim Term with Citations to Supporting Evidence
`
`
`Term To Be
`Construed
`
`Cubist’s Proposed
`Construction
`
`Hospira’s Proposed
`Construction
`
`Intrinsic Evidence
`Intrinsic Evidence
`Supporting Hospira’s
`Supporting Cubist’s
`Construction
`Construction
`
`
` Col. 1, lns. 26-35
`
`‘07 1 Patent Specification
`
`Abstract
`
`Col. 2, lns. 29-31
`
`Col. 7, ln. 1 —Col. 8, In. 25
`
`C01. 8, lns. 46-67
`
`Col. 15, In. 50 — Col. 17,
`In. 4 (Claim 18)
`
`C01. 17, In. 8 — Col. 19,
`In. 30 (Claim 20)
`
`C01. 20, In. 26 — Col. 22,
`In. 45 (Claim 26)
`
`C01. 23, ln. 1 — Col. 26,
`In. 6 (Claim 30)
`
`“formula 3
`compound”/
`“compound of
`f0f111111a 3”
`
`An A21978C cyclic
`peptide of
`
`FORMLlA 3
`
`(Claims 18, 26,
`28 of the ‘071
`
`patent)
`
`/L-Asp
`D—Jfla
`L-Asp
`. {I